Cargando…

Synthesis, Biological Activity and Molecular Docking Studies of Novel Nicotinic Acid Derivatives

In our research, we used nicotinic acid as a starting compound, which was subjected to a series of condensation reactions with appropriate aldehydes. As a result of these reactions, we were able to obtain a series of twelve acylhydrazones, two of which showed promising activity against Gram-positive...

Descripción completa

Detalles Bibliográficos
Autores principales: Paruch, Kinga, Biernasiuk, Anna, Khylyuk, Dmytro, Paduch, Roman, Wujec, Monika, Popiołek, Łukasz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8911400/
https://www.ncbi.nlm.nih.gov/pubmed/35269966
http://dx.doi.org/10.3390/ijms23052823
_version_ 1784666792978808832
author Paruch, Kinga
Biernasiuk, Anna
Khylyuk, Dmytro
Paduch, Roman
Wujec, Monika
Popiołek, Łukasz
author_facet Paruch, Kinga
Biernasiuk, Anna
Khylyuk, Dmytro
Paduch, Roman
Wujec, Monika
Popiołek, Łukasz
author_sort Paruch, Kinga
collection PubMed
description In our research, we used nicotinic acid as a starting compound, which was subjected to a series of condensation reactions with appropriate aldehydes. As a result of these reactions, we were able to obtain a series of twelve acylhydrazones, two of which showed promising activity against Gram-positive bacteria (MIC = 1.95–15.62 µg/mL), especially against Staphylococcus epidermidis ATCC 12228 (MIC = 1.95 µg/mL). Moreover, the activity of compound 13 against the Staphylococcus aureus ATCC 43300 strain, i.e., the MRSA strain, was MIC = 7.81 µg/mL. Then, we subjected the entire series of acylhydrazones to a cyclization reaction in the acetic anhydride, thanks to which we were able to obtain twelve new 3-acetyl-2,5-disubstituted-1,3,4-oxadiazoline derivatives. Obtained 1,3,4-oxadiazolines were also tested for antimicrobial activity. The results showed high activity of compound 25 with a 5-nitrofuran substituent, which was active against all tested strains. The most promising activity of this compound was found against Gram-positive bacteria, in particular against Bacillus subtilis ATCC 6633 and Staphylococcus aureus ATCC 6538 (MIC = 7.81 µg/mL) and ATCC 43300 MRSA strains (MIC = 15.62 µg/mL). Importantly, the best performing compounds did not show cytotoxicity against normal cell lines. It seems practical to use some of these compounds or their derivatives in the future in the prevention and treatment of infections caused by some pathogenic or opportunistic microorganisms.
format Online
Article
Text
id pubmed-8911400
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89114002022-03-11 Synthesis, Biological Activity and Molecular Docking Studies of Novel Nicotinic Acid Derivatives Paruch, Kinga Biernasiuk, Anna Khylyuk, Dmytro Paduch, Roman Wujec, Monika Popiołek, Łukasz Int J Mol Sci Article In our research, we used nicotinic acid as a starting compound, which was subjected to a series of condensation reactions with appropriate aldehydes. As a result of these reactions, we were able to obtain a series of twelve acylhydrazones, two of which showed promising activity against Gram-positive bacteria (MIC = 1.95–15.62 µg/mL), especially against Staphylococcus epidermidis ATCC 12228 (MIC = 1.95 µg/mL). Moreover, the activity of compound 13 against the Staphylococcus aureus ATCC 43300 strain, i.e., the MRSA strain, was MIC = 7.81 µg/mL. Then, we subjected the entire series of acylhydrazones to a cyclization reaction in the acetic anhydride, thanks to which we were able to obtain twelve new 3-acetyl-2,5-disubstituted-1,3,4-oxadiazoline derivatives. Obtained 1,3,4-oxadiazolines were also tested for antimicrobial activity. The results showed high activity of compound 25 with a 5-nitrofuran substituent, which was active against all tested strains. The most promising activity of this compound was found against Gram-positive bacteria, in particular against Bacillus subtilis ATCC 6633 and Staphylococcus aureus ATCC 6538 (MIC = 7.81 µg/mL) and ATCC 43300 MRSA strains (MIC = 15.62 µg/mL). Importantly, the best performing compounds did not show cytotoxicity against normal cell lines. It seems practical to use some of these compounds or their derivatives in the future in the prevention and treatment of infections caused by some pathogenic or opportunistic microorganisms. MDPI 2022-03-04 /pmc/articles/PMC8911400/ /pubmed/35269966 http://dx.doi.org/10.3390/ijms23052823 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Paruch, Kinga
Biernasiuk, Anna
Khylyuk, Dmytro
Paduch, Roman
Wujec, Monika
Popiołek, Łukasz
Synthesis, Biological Activity and Molecular Docking Studies of Novel Nicotinic Acid Derivatives
title Synthesis, Biological Activity and Molecular Docking Studies of Novel Nicotinic Acid Derivatives
title_full Synthesis, Biological Activity and Molecular Docking Studies of Novel Nicotinic Acid Derivatives
title_fullStr Synthesis, Biological Activity and Molecular Docking Studies of Novel Nicotinic Acid Derivatives
title_full_unstemmed Synthesis, Biological Activity and Molecular Docking Studies of Novel Nicotinic Acid Derivatives
title_short Synthesis, Biological Activity and Molecular Docking Studies of Novel Nicotinic Acid Derivatives
title_sort synthesis, biological activity and molecular docking studies of novel nicotinic acid derivatives
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8911400/
https://www.ncbi.nlm.nih.gov/pubmed/35269966
http://dx.doi.org/10.3390/ijms23052823
work_keys_str_mv AT paruchkinga synthesisbiologicalactivityandmoleculardockingstudiesofnovelnicotinicacidderivatives
AT biernasiukanna synthesisbiologicalactivityandmoleculardockingstudiesofnovelnicotinicacidderivatives
AT khylyukdmytro synthesisbiologicalactivityandmoleculardockingstudiesofnovelnicotinicacidderivatives
AT paduchroman synthesisbiologicalactivityandmoleculardockingstudiesofnovelnicotinicacidderivatives
AT wujecmonika synthesisbiologicalactivityandmoleculardockingstudiesofnovelnicotinicacidderivatives
AT popiołekłukasz synthesisbiologicalactivityandmoleculardockingstudiesofnovelnicotinicacidderivatives